Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ: RVMD ) with a Buy and raises the price target from $210 to $231.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.